Skip to main content

Table 3 Skin infections in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy

From: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

  

Time to event

      

Infection

No. of events

Median

Range

Druga (no.)

Active treatmentb (no.)

Rechallenge (no.)

Permanent withdrawal of anti-TNF-αc (no.)

Biopsy (no.)

Cultured species

Fungal

20

8.7

1.1–61.1

      

   Dermatomycosis

9

  

A 3, I 4, E 2

7

 

0

1

Trichophyton verrucosum (1) T. rubrum (1)

   Onychomycosis

3

  

A 3

3

 

0

0

 

   Combination

5

  

A 3, I 1, L 1

4

 

0

1

Trichophyton rubrum (3) T. mentagrofytes (1)

   Candidiasis

3

  

I 3

2

 

0

0

Candida spp. (2)

Bacterial

11

9.5

1.4–52.5

      

   Folliculitis

5

  

A 3, E 2

4

yes, negative

1

2

Staphylococcus aureus (1)

   Erysipelas

3

  

E 2, I 1

3

yes, negative

2

1

 

   Bacterial superinfection of eczema

2

  

A 1, I 1

1

yes, positive

1

0

 

   Furuncle

1

  

I 1

0

 

0

0

 

Viral – herpes zoster

2

17.3, 40.9d

 

A 1, I 1

0

 

0

0

 
  1. aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bDuring active treatment with TNF-α-blocking therapy. cPermanent discontinuation of TNF-α-blocking therapy due to the event.d Individual values